Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the appointment of Michael Tomsicek as Senior Vice President and Chief Financial Officer (CFO). Mr. Tomsicek, who has served as Senior Vice President and Deputy CFO since July 2012, succeeds David McGirr. After more than a decade of leadership at Cubist, Mr. McGirr will serve as Senior Advisor to the Chief Executive Officer (CEO), and retire in 2014.
Michael Tomsicek, Cubist CFO (Photo: Business Wire)
“David has been an outstanding contributor to Cubist’s success over the past decade,” said Mike Bonney, Cubist’s CEO. "He helped build the strong financial foundation that Cubist and our shareholders benefit from today. We appreciate his dedication to Cubist and are pleased he will continue to serve the Company during this time of transition. In addition, a critical component of our Building Blocks of Growth strategic goals has been cultivating top talent, and we are very fortunate to have a successor in Michael who can step into this important role and help continue our excellent momentum as we begin our next chapter as a Company.”
Mr. McGirr said, "I’ve enjoyed working closely with Mike and everyone at Cubist as CFO over the past decade and am proud to have helped the Company become a global leader in the hospital and acute care environment, help countless patients, and generate significant value for shareholders. I believe now is the right time for a transition and am confident Michael will serve Cubist very well as our CFO.”
“I have been fortunate to work closely with David to ensure a smooth transition into my expanded role,” said Mr. Tomsicek. “With a strong financial foundation, an exceptional late-stage pipeline, and an emerging global presence, this is an exciting time at Cubist. I look forward to helping the Company continue to grow and expand in the years ahead.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts